Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8962429 | 0.81 | — | — | |
| SCHEMBL9391001 | 0.79 | LMNA (0.44) | LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL8962989 | 0.79 | KMT2A (0.48) | LMNAKMT2A | |
| SCHEMBL8962467 | 0.78 | MAPK1 (0.43) | NLRP3 | |
| SCHEMBL8962780 | 0.76 | — | — | |
| SCHEMBL8962444 | 0.75 | SOAT2 (0.41) | LMNAKMT2A | |
| SCHEMBL7082105 | 0.74 | NLRP3 (0.50) | LMNAKMT2ANLRP3 | |
| SCHEMBL8962380 | 0.73 | LMNA (0.47) | LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL8962531 | 0.73 | SMN1; SMN2 (0.47) | LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL11234113 | 0.72 | L3MBTL1 (0.63) | LMNAKMT2ASMN1; SMN2NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996019446-A1 | β-CARBOXY SULFONAMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-06-27 | — | — | WO | claimed |
| WO-1996019446-A1 | β-CARBOXY SULFONAMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-06-27 | — | — | WO | disclosed |
| US-5491170-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | disclosed |